Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Depressive symptoms are common in patients with asthma and are consistently linked to poorer disease control and greater severity. However, emerging evidence suggests that asthma-related depression may be biologically distinct from 

, with elevated levels of brain-derived neurotrophic factor (BDNF) in patients with 

In this multicenter observational study, investigators analyzed data from 140 adults with asthma enrolled in the Physical Activity in Bronchial Asthma (PACTAS) study. Serum BDNF levels were measured using an enzyme-linked immunosorbent assay, while depressive and anxiety symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS). Daily physical activity was objectively quantified using a triaxial accelerometer.

Contrary to patterns seen in MDD, where reduced BDNF is a hallmark, serum BDNF levels were positively associated with depressive symptom severity in patients with asthma (

<.001). Patients with clinically relevant depressive symptoms (HADS-D ≥8) had significantly greater BDNF levels than those without.

Elevated BDNF was also independently associated with greater asthma severity, as reflected by higher treatment step, and poorer asthma control. Exploratory mediation analyses suggested that BDNF may partially mediate the relationship between asthma severity and depressive symptoms. These findings suggest that depressive symptoms in asthma may reflect disease-related inflammatory or stress pathways rather than the neurotrophic deficits characteristic of primary depression.

conducted a Q&A with investigator Hiroshi Iwamoto, MD, PhD, from Hiroshima University in Japan, on clinical implications of these findings and how they may inform a more integrated approach to managing asthma and mental health.

How should clinicians rethink depressive symptoms in asthma, given that higher—not lower—BDNF levels were associated with worse mood?Iwamoto:

 Clinicians should consider that depressive symptoms in asthma may not share the same biological background as primary major depressive disorder. In asthma, elevated BDNF may reflect physiological stress or disease burden.

What does the association between elevated BDNF and asthma severity reveal about the brain–lung axis in chronic airway disease?Iwamoto:

 Our study does not provide direct evidence of a brain–lung axis. Rather, it shows an association between asthma severity, circulating BDNF levels, and depressive symptoms, which may warrant further mechanistic investigation.

Do your findings suggest that depressive symptoms in asthma are more closely linked to disease burden than to primary major depressive disorder?Iwamoto:

 Yes. Our results indicate that depressive symptoms in asthma appear to be more closely associated with asthma severity and disease burden than with the biological profile typically seen in primary major depressive disorder.

How should clinicians address poor asthma control and physical inactivity when managing depressive symptoms in patients with asthma?Iwamoto:

 Management may benefit from optimizing asthma control and addressing physical inactivity, alongside screening and support for depressive symptoms, rather than focusing solely on psychiatric treatment.

Given that antidepressants increase BDNF in major depressive disorder, how should clinicians interpret elevated BDNF levels in patients with asthma who have depressive symptoms?Iwamoto:

 In asthma, elevated BDNF should not automatically be interpreted as a marker of antidepressant response. It may instead reflect asthma-related inflammation or stress, although patients with comorbid major depressive disorder may still benefit from antidepressant therapy.

What are the limitations of applying traditional depression biomarkers or frameworks to patients with asthma based on your data?Iwamoto:

 Traditional biomarkers and frameworks derived from major depressive disorder may not fully capture the mechanisms of asthma-related depressive symptoms.

Is there a realistic future role for serum BDNF as a clinical biomarker in asthma, or is its value primarily mechanistic at this stage?Iwamoto:

 At present, the value of serum BDNF is primarily mechanistic. Its potential role as a clinical biomarker will require validation in longitudinal and interventional studies.

Based on your findings, what should an integrated, day-to-day clinical approach to asthma-related depressive symptoms look like today?Iwamoto:

 An integrated approach should address asthma control, physical activity, and mental health simultaneously, with collaboration between respiratory and mental health care when needed.

What further research is needed on this topic?Iwamoto:

 Further longitudinal and interventional studies are needed to clarify the temporal and causal relationships between asthma severity, BDNF levels, and depressive symptoms, and to determine whether BDNF can help stratify depressive symptoms or guide personalized management in asthma.

Kawamoto K, Iwamoto H, Hirano T, et al. Brain-Derived Neurotrophic Factor Levels Are Associated With Depressive Symptoms in Patients With Asthma. 

. Published online November 11, 2025. doi:10.1016/j.jaip.2025.11.001

Articles

Depressive symptoms in asthma patients are linked to elevated brain-derived neurotrophic factor (BDNF) levels, contrasting with major depressive disorder (MDD) where reduced BDNF is typical. This suggests asthma-related depression may stem from disease-related inflammatory or stress pathways rather than neurotrophic deficits. Elevated BDNF correlates with greater asthma severity and poorer control. Clinicians should consider integrated management addressing asthma control, physical activity, and mental health. Further research is needed to explore BDNF's potential as a biomarker and its role in personalized asthma management.

New data suggest asthma-related depression may be biologically distinct from MDD, with greater serum BDNF tied to worse disease severity and lower physical activity.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Elevated BDNF Linked to Depressive Symptoms in Patients with Asthma, With Hiroshi Iwamoto, MD, PhD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Nicole DeCleene, BS | Image Credit: LinkedIn

Despite substantial differences by race, ethnicity, sex, age, and geographical location, 

 prevalence is high and expected to increase across all groups in the US, according to a recent study.

Obesity, defined in the present study as a body mass index (BMI) ≥30, has increased drastically in prevalence over the last few decades. Its association with a slew of serious health risks, including 

 and end-stage renal disease, establishes obesity as 1 of the most substantial detriments to public health nationwide.

“Despite the significant impact obesity has had on public health and the importance of tracking its trends for policy setting, recently updated estimates for current rates of obesity prevalence and projected future trends are not available by race and ethnicity subgroups within US states,” wrote Nicole DeCleene, BS, Institute for Health Metrics and Evaluation, University of Washington, and colleagues.

The team utilized cross-sectional data on BMI from 2 nationally representative, state-level surveys – the Behavioral Risk Factor Surveillance System (BRFSS) and Gallup Daily Survey, covering 1988-2022 and 2008-2017, respectively. With these self-reported data, investigators estimated the mean BMI and obesity prevalence from 1990 to 2022 and forecasted their growth through 2035.

Data from the National Health and Nutrition Examination Survey (NHANES) were utilized to correct for the inherent bias of self-reported data. Mean self-reported BMI from Gallup and BRFSS were matched with mean measured BMI in NHANES by sex, age, race and ethnicity, survey year, and quantiles of self-reported BMI. The prevalence of obesity was estimated via estimates of mean BMI, standard deviation, and distribution shape.

In total, 11,315,421 participants were included – 11,243,644 were sourced from BRFSS and Gallup, while 71,777 were obtained from NHANES. Obesity prevalence increased substantially across the entire US population since 1990; the estimated total of individuals ≥20 years living with obesity has increased from 34.7 million (95% uncertainty interval [UI], 31.1-38.3) in 1990 to 107 million (95% UI, 101-113) in 2022. This represents an increase from 19.3% (95% UI, 17.3-21.3%) to 42.5% (95% UI, 40.2-45%) of the population.

Notably, however, this increase has not been consistent by group at a national level; non-Hispanic Black males have seen the least increase in obesity prevalence, while the largest increases were among Hispanic females – from 24.2% (95% UI, 21.3-27.3%) to 49.4% (95% UI, 46.3-52.4%) – and males – from 17.4% (95% UI, 14.7-20.4%) to 42.6% (95% UI, 39.1-46.2%).

By 2035, DeCleene and colleagues estimated that the number of individuals ≥20 years living with obesity would reach 126 million (95% UI, 118-134), or 46.9% of the population (95% UI, 43.9-49.9%). Age-standardized obesity prevalence was predicted to reach 53.7% (95% UI, 48.7-57.7%) for Hispanic females and 47.5% (95% UI, 42.5-51.9%) for Hispanic males.

Across all population groups, obesity prevalence was highest between ages 45 and 64 years, and lower at the youngest and oldest ages. Females saw the largest increase in obesity prevalence among those <35 years, while males saw no consistent pattern by age for any of the 3 race and ethnicity groups.

Ultimately, DeCleene and colleagues highlighted significant disparities in the estimated prevalence of obesity by race and ethnicity group, particularly in females. Substantial increases have occurred among younger ages since 1990, representing an earlier onset. Additionally, the team noted that a lower prevalence of obesity at older ages likely represents premature mortality for those living with obesity. The prevalence of obesity in 2035 is projected to increase to 46.9% (95% UI, 43.9%-49.9%) of the US adult population.

“The patterns of obesity shown in the current analysis demonstrate significant health disparities that are likely to continue,” DeCleene and colleagues wrote. “Studies suggest that these disparities are the result of a complex and multifactorial set of causes, including discrimination based on race and ethnicity group, food insecurity and differential access to healthy food, socioeconomic deprivation, and inequities in physical activity access due to neighborhood segregation and aspects of the built environment.”

DeCleene NK, Kahn E, Yuan C-W, et al. US state-level prevalence of adult obesity by race and ethnicity from 1990 to 2022 and forecasted to 2035. JAMA. Published online January 28, 2026. 

Hales CM﻿, Carroll MD﻿, Fryar CD﻿, Ogden CL﻿. Prevalence of Obesity and Severe Obesity among Adults: United States, 2017-2018. NCHS Data Brief No. 360. National Center for Health Statistics. Published 2020. Accessed December 23, 2025. 

https://stacks.cdc.gov/view/cdc/85451/cdc_85451_DS1.pdf

Obesity prevalence in the US is high and projected to increase across all demographics, with significant disparities by race, ethnicity, and sex. Utilizing data from BRFSS, Gallup, and NHANES, researchers estimated obesity trends from 1990 to 2022 and forecasted through 2035. The study found substantial increases in obesity, particularly among Hispanic females and males, with the highest prevalence in individuals aged 45-64. Disparities are attributed to factors like discrimination, food insecurity, and socioeconomic deprivation. By 2035, obesity is expected to affect 46.9% of the US adult population.

Since 1990, the prevalence of individuals with a BMI ≥30 has increased dramatically, and without significant intervention, will continue to do so.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Obesity Prevalence in US Increasing Drastically, Expected to Continue into 2035

Holly Kramer, MD, is a nephrologist at Loyola University Medical Center and the editor in chief of 

Utilizing Diet to Prevent Obesity, Preserve Kidney Function, With Holly Kramer, MD

and the risk the comorbidity poses to renal function may alleviate the development of 

 before end-stage kidney disease (ESKD), according to an expert.

New insights from Holly Kramer, MD, a nephrologist at Loyola University Medical Center and editor in chief of 

, suggest clinical management, especially referring patients to dieticians early, can temper the pathophysiological mechanisms of obesity, which independently contribute to renal injury.

While obesity has been independently associated with CKD progression, certain individuals may be predisposed to the glomerular effects based on their nephron number from birth. Their nephron endowment can range from 200,000 to 2 million per kidney, and is determined by genetic and environmental factors during gestation. 

A reduced nephron endowment increases the risk for hypertension and CKD due to reduced renal functional capacity and compensatory glomerular hypertrophy. Other causes of reduced nephron count include premature birth, genetics, or conditions like diabetes or chemotherapy.

When an individual has obesity, the kidney’s response is to increase glomerular capillary pressure, intraglomerular flow, and filtration at the level of each nephron. When intraglomerular hypertension is sustained, it can lead to mechanical stress on the glomerular basement membrane, podocyte injury and loss, glomerulosclerosis, progressive nephron dropout, and proteinuria.

Once nephron depletion transpires, an individual's remaining nephrons become exposed to increased levels of hyperfiltration, reinforcing a feedback loop. This fuels the hyperfiltration hypothesis of CKD progression, with obesity revealing itself as a strong physiologic driver.

“So it's kind of like if you had a shoe factory and you fire, you know, three fourths of your employees, and then all of a sudden you say, Oh, by the way, we have to make three times as many shoes as what we normally do, you know,” explained Kramer, in an interview with 

“And so people get tired in that shoe factory. Same thing with those nephrons. In the setting of obesity and reduced nephron number, they just kind of wear out.”

At increased levels of body mass index (BMI), especially those > 40, systemic inflammation increases, adipokine signaling alters renal hemodynamics, and insulin resistance worsens glomerular stress. Additionally, patients often experience comorbidities of hypertension and diabetes, which can cause more damage to the kidneys.

Often, clinical management of these symptoms can be delayed until patients reach ESKD and are on maintenance dialysis. Once patients reach this stage, obesity can pose barriers to receiving a transplant because of increased risk for complications during and after surgery.

“Only about 10% of patients ever meet with a registered dietitian. But when they get on dialysis, everybody talks with the dietitian,” said Kramer. “It really makes sense that we should try to get our patients to be talking with a registered dietitian to slow kidney disease progression and get them to eat healthier.”

Kramer emphasizes the importance of medical nutrition therapy, which is covered by Medicare and most private insurances, and is crucial for managing kidney disease. She encourages patients to consult registered dietitians, either through telehealth or via the National Kidney Foundation's directory, to take disease management into their own hands, slow kidney disease and adopt healthier eating habits.

Kovesdy CP, Furth SL, Zoccali C. Obesity and Kidney Disease. 

Canadian Journal of Kidney Health and Disease

Villani G, Zaza P, Lamparelli R, Maffei G. Kidney volume-to-birth weight ratio as an estimate of nephron endowment in extremely low birth weight preterm infants. 

https://doi.org/10.1038/s41598-024-64897-6

Good PI, Li L, Hurst HA, et al. Low nephron endowment increases susceptibility to renal stress and chronic kidney disease. 

https://doi.org/10.1172/jci.insight.161316

Garske KM, Kar A, Comenho C, et al. Increased body mass index is linked to systemic inflammation through altered chromatin co-accessibility in human preadipocytes. 

https://doi.org/10.1038/s41467-023-39919-y

National Kidney Foundation. Nutrition and Kidney Disease, Stages 1-5 (Not on Dialysis). National Kidney Foundation. Published 2024. 

https://www.kidney.org/kidney-topics/nutrition-and-kidney-disease-stages-1-5-not-dialysis

Videos

Clinicians can provide dietitian intervention to reduce the risk of obesity, which is independently associated with CKD.  


Sina Kianersi, PhD, is a research fellow in medicine at Brigham and Women’s Hospital.

Staying Up Late Associated With CVD Risk Through Worse LE8 Scores, With Sina Kianersi, PhD

Individuals with an evening chronotype, or “night owls,” may be at greater risk of 

; however, a significant percentage of contributing factors are modifiable.

During the 14-year trial, participants with a “definitely evening” chronotype – defined as having a late-night bedtime such as 2 a.m. and peak activity later in the day – were associated with a 79% higher prevalence of overall poor Life’s Essential 8 (LE8) scores. By the end of the trial, investigators had recorded 17,584 incident cardiovascular disease events.

“The encouraging part of our findings, however, is that roughly 75% of that difference seemed to be explained by modifiable factors such as sleep, physical activity, smoking, weight, blood pressure, cholesterol, and blood sugar,” Sina Kianersi, PhD, research fellow in medicine at Brigham and Women’s Hospital, told 

Kianersi and colleagues conducted a prospective study using UK Biobank assessment center visits as the baseline. A total of 502,128 patients were initially included in the dataset – of these, 6172 were excluded due to missing chronotype information, 18,292 were excluded due to a history of myocardial infarction (MI) or 

 at baseline, and 154,887 were excluded due to incomplete data on ≥1 lifestyle behaviors or factors among LE8. A total of 322,777 patients were ultimately enrolled and followed up over a duration of 14 years.

Chronotype was self-reported at baseline visit using a single question from the Morningness-Eveningness Questionnaire. This question’s correlation coefficient with the full questionnaire score surpasses 0.72. The LE8 framework is composed of 4 health behaviors – diet, physical activity, nicotine exposure, and sleep health – and 4 health factors – body weight, blood lipids, blood glucose, and blood pressure. Each component has a scoring algorithm from 0 to 100, with higher scores indicating better cardiovascular health. Diet, physical activity, sleep duration, and nicotine exposure were self-reported, while weight, blood lipids, blood glucose, and blood pressure were measured directly.

The mean age of the study population was 57 years (+/- standard deviation [SD] 8). Roughly 58% of participants had a family history of cardiovascular disease. The majority of participants (67%) had an “intermediate” chronotype, with 8% reporting a "definitely evening" chronotype. Compared with the “intermediate” chronotype, those with a “definitely evening” chronotype were younger, were more frequently engaged in shift work (12% vs 9%), more frequently held college degrees (43% vs 37%), and had a lower overall LE8 score (65 vs 68). In a descriptive analysis, “definitely evening” participants had notably poorer scores in 7 of 8 components compared to the “intermediate” participants.

Ultimately, after a median follow-up of 13.8 years (interquartile range [IQR], 1.6), 17,584 incident cardiovascular disease cases (MI = 11,091; stroke = 7214) were documented among all participants. Compared with the “intermediate” chronotype, those with a “definitely evening” chronotype had a 16% higher risk of cardiovascular disease (HR, 1.16; 95% CI, 1.1-1.22), while those reporting “definitely morning” chronotypes were not at an increased risk (HR, 1.03; 95% CI, 0.99-1.07). After adjusting for the 8 LE8 components, associations attenuated; however, no direct effect of evening chronotype on cardiovascular disease was observed, as the natural indirect effect, representing the effect mediated by the overall LE8 score, was 1.11 (95% CI, 1.09-1.13). This indicated that 75% of the association between chronotype and incident cardiovascular disease was mediated through these scores.

Ultimately, although evening chronotype was directly associated with a poorer score in LE8, this renders it reversible through alterations to diet, physical activity, and nicotine exposure, among other factors. Kianersi and colleagues emphasized that chronotype had no direct influence on cardiovascular disease.

“One of the limitations of the study is that we followed the cohort for about 14 years, and the risk is for that specific number of years,” Kianersi said. “The risk might be different for shorter or longer study periods – it might change if we follow participants for a longer time, as we had in our previous studies.”

Editor’s Note: Kianersi reports no relevant disclosures.

American Heart Association. Being a night owl may increase your heart risk. 

. January 28, 2026. Accessed January 29, 2026. 

https://www.eurekalert.org/news-releases/1113759

Kianersi S, Potts KS, Wang H, et al. Chronotype, life’s essential 8, and risk of cardiovascular disease: A prospective cohort study in UK Biobank. Journal of the American Heart Association. Published online January 28, 2026. 

Kianersi discusses how, although evening chronotype can be associated indirectly with increased CVD risk, this can be mediated via Life’s Essential 8 scores.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Highlighting Therapeutic Updates for Atopic Dermatitis and Itch, With Lawrence Eichenfield, MD

, the ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026’ talk was presented, with 3 speakers highlighting the emergence of monoclonal antibodies, oral Janus Kinase (JAK) inhibitors, and topical non-steroidal drugs into dermatology practices.

Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics at the UC San Diego School of Medicine, was 1 such presenter. Eichenfield spoke in an interview with 

“My duty was to go through some of the topical treatments, and that's been a remarkably rapidly changing place,” Eichenfield explained. “I went through what I called our sort of new, younger non-steroids and our more senior non-steroid topicals.”

Throughout their session, Eichenfield and his fellow panelists covered advancements in dermatology, focusing on topical drugs and systemic medicines. The updates included the US Food and Drug Administration (FDA) approval of new non-steroidal topicals such as tapinarof and ruxolitinib.

They also touched on the extended approval of ruxolitinib for younger patients. In their talk, the panelists’ discussion also covered the importance of managing topical steroid withdrawal, also known as TSW. The 3 panelists highlighted counseling in atopic dermatitis and systemic treatments for children as young as 6 months with the skin disease.

Eichenfield was asked about future developments in the dermatology field in 2026, including OX40 and IL-13 mediator pathway targets. Alopecia areata and vitiligo were described as continuing to see significant research, with topical ruxolitinib showing promise.

To find out more insights on various dermatologic conditions, view updates to coverage of the 

The quotes included in this video summary were edited for clarity.

Disclosures: Eichenfield previously reported receiving personal fees from Pfizer Inc; grant funding from AbbVie, Arcutis Biotherapeutics, Bausch + Lomb, Castle Biosciences, Dermavant Sciences Inc, Galderma SA, Pfizer Inc, Regeneron, and Sanofi SA and consulting for ASLAN Pharmaceuticals, AbbVie, Almirall, SA, Arcutis Biotherapeutics, Arena Pharmaceuticals Inc, Dermavant Sciences Inc, Galderma SA, Incyte Corporation, LEO Pharma A/S, Eli Lilly and Company, Ortho Dermatologics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi SA, and UCB; and serving on the board of directors of Forté Pharma.

Eichenfield L, Silverberg J, Chovatiya R. Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Gallagher K, Halperin-Goldstein S, Paller AS. New treatments in atopic dermatitis update. Ann Allergy Asthma Immunol. 2025 Nov;135(5):498-510.e10. doi: 10.1016/j.anai.2025.06.020. Epub 2025 Jun 23. PMID: 40562170.

At the Maui Derm Hawaii 2026 conference, Lawrence Eichenfield, MD, spoke about highlights from his talk, ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026.’

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

This interview with Stein Gold continues her discussion of new and emerging psoriasis therapies in 2026.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Emerging Psoriasis, PsA Drugs and Future Developments in Dermatology, With Linda Stein Gold, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

ASH’s multidisciplinary panel provides a standardized diagnostic pathway emphasizing early laboratory testing and surrogate biopsies.

Hematology

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

Noureddin recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASH Pipeline Developments and Emerging Therapies to Watch in 2026, With Mazen Noureddin, MD, MHSc

This interview at the 2026 Maui Derm Hawaii meeting features a discussion of new and emerging therapies in psoriasis, including icotrokinra.

Discussing Icotrokinra for Adolescents, Other Emerging Psoriasis Drugs, With Linda Stein Gold, MD

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Podcasts

Reau and Brown discuss new data on MASH/MASLD, including awareness, referral patterns, discussions around alcohol, and emerging pharmacotherapies.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors

The new approval allows for repeat administration of iDose TR, modifying the existing single-administration label.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

FDA News

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

In a 31-center phase 2 trial in 10 countries, apecotrep BI 764198 reduced proteinuria in patients with primary focal segmental glomerulosclerosis.  


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

Ruth Frikke-Schmidt, MD, PhD, is a professor and chief physician at Copenhagen University Hospital.

Frikke-Schmidt discusses the newfound genetic correlation between vascular-related dementia and an increased BMI, partially mediated by high blood pressure.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Connecting Vascular Dementia to Obesity and High Blood Pressure, With Ruth Frikke-Schmidt, MD, PhD

Alexander Mathioudakis, MD, PhD, from the biology department at The University of Manchester.

In this Q&A, Mathioudaki discusses the post-hoc FLAME trial, which links ICS and LAMA discontinuation to transient exacerbation risk in COPD.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

At the 2026 Maui Derm Hawaii meeting, recent data on icotrokinra’s use in patients with psoriasis were highlighted.

Latest News

Elevated BDNF Linked to Depressive Symptoms in Patients with Asthma, With Hiroshi Iwamoto, MD, PhD

Obesity Prevalence in US Increasing Drastically, Expected to Continue into 2035

Utilizing Diet to Prevent Obesity, Preserve Kidney Function, With Holly Kramer, MD

Staying Up Late Associated With CVD Risk Through Worse LE8 Scores, With Sina Kianersi, PhD

Highlighting Therapeutic Updates for Atopic Dermatitis and Itch, With Lawrence Eichenfield, MD